Literature DB >> 6087704

Aldosterone-producing adrenocortical carcinoma. Preoperative recognition and course in three cases.

E Arteaga, E G Biglieri, C E Kater, J M Lopez, M Schambelan.   

Abstract

Three patients with primary aldosteronism due to adrenocortical carcinoma were studied, two with hyperaldosteronism alone and one also with hypercortisolism; in the later stages all three had hypersecretion of glucocorticoid and androgenic hormones. Although clinical presentations were similar to those of patients with benign adenoma, all had significantly higher concentrations of deoxycorticosterone and aldosterone and more profound hypokalemia. Stimulation with adrenocorticotropin in two patients showed a good cortisol response but no aldosterone response. The circadian rhythm for cortisol was normal but absent for aldosterone and deoxycorticosterone. Sequential 24-hour circadian studies in one patient showed that as the disease progressed, corticosterone and finally cortisol lost their circadian rhythms. Treatment with spironolactone, mitotane, or aminoglutethimide had transient clinical effects. The patients died 2 to 13 years later.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087704     DOI: 10.7326/0003-4819-101-3-316

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

Review 1.  Current perspective in the diagnosis and treatment of adrenocortical carcinoma.

Authors:  D E Schteingart
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

2.  Hyperaldosteronism combined with hypercortisolaemia in a patient with adrenal carcinoma.

Authors:  N S Panesar; S Y Tsao; M J Wheeler; C S Cockram
Journal:  Postgrad Med J       Date:  1988-04       Impact factor: 2.401

3.  Primary hyperaldosteronism caused by adrenocortical carcinoma.

Authors:  H W Scott; C R Sussman; D L Page; N W Thompson; M D Gross; R Lloyd
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.